BACKGROUND: Herein, the authors evaluated how the time to testosterone rebound (TTR) after radiotherapy (RT) and 6 months of androgen deprivation therapy (ADT) impacted the risk of prostate cancer-specific mortality (PCSM) and cardiovascular-specific mortality (CVM) among men with varying comorbidity extent. METHODS: Between 1995 and 2001, a total of 206 men who were randomized to receive RT either alone or with 6 months of ADT for unfavorable-risk PC and who had a comorbidity score assigned using the Adult Comorbidity Evaluation 27 metric comprised the study cohort. Multivariable competing risk regression was used to evaluate the impact of and possible interaction between comorbidity and TTR on PCSM and CVM. RESULTS: After a median follow-up of 18.19 years, 30 men (18.6%), 39 men (24.2%), and 92 men (57.1%), respectively, had died of PC, CV disease, or other causes. As TTR increased, PCSM significantly decreased in men with no or minimal (adjusted hazard ratio [AHR], 0.53, 95% confidence interval [95% CI], 0.34-0.84 [P 5.007]) and moderate to severe (AHR, 0.37; 95% CI, 0.14-0.99 [P 5 .048]) comorbidity. However, increasing TTR significantly increased the risk of CVM among men with moderate to severe comorbidity (AHR, 1.87; 95% CI, 1.40-2.49 [P <.001]), but not those with no or minimal comorbidity (AHR, 0.86; 95% CI, 0.57-1.29 [P 5.46]), leading to a significant interaction between TTR and comorbidity (P 5 .001). CONCLUSIONS: The results of the current study indicate that considering an intermittent course of ADT such that the TTR approaches 18 months, instead of continuous long-term administration of ADT, in men with moderate to severe comorbidity and high-risk PC may reduce the increased risk of CVM without increasing the risk of PCSM. Cancer 2018;124:1391-9. V C 2018 American Cancer Society.
INTRODUCTION
The use of radiotherapy (RT) and androgen deprivation therapy (ADT) is an accepted standard of care for men with unfavorable-risk prostate cancer (PC) based on the survival benefit observed in several prospective randomized controlled trials 1,2 when compared with RT alone. However, controversy exists regarding whether the increased risk of fatal cardiovascular (CV) events observed with the use of ADT in men with moderate to severe comorbidity is causal or an association. [3] [4] [5] [6] [7] Fortunately, Radiation Therapy Oncology Group study RTOG 0815 is a prospective randomized trial of men with intermediate-risk PC that randomized men to high-dose RT with or without 6 months of ADT and stratified men before randomization by comorbidity using the Adult Comorbidity Evaluation 27 metric 8 (ACE-27) and hopefully will resolve this controversy.
In the interim, physicians are faced with the challenge of whether to administer ADT in conjunction with RT in men with moderate to severe comorbidities who have the indication based on the diagnosis of unfavorable-risk PC. Given the known variation among men in time to testosterone rebound (TTR) after the administration of ADT, which is agedependent, [9] [10] [11] [12] an opportunity may exist to tailor ADT administration based on the TTR as opposed to an absolute number of months of prescribed ADT to minimize CV-specific mortality (CVM). However, to the best of our knowledge, the question of how increasing TTR affects the risk of CVM in men with a varying extent of comorbidities is unknown.
Therefore, the purpose of the current study was to evaluate how the TTR after RT and 6 months of ADT impacted the prostate cancer-specific mortality (PCSM) and CVM, as well as all-cause mortality (ACM) among men with no or minimal versus moderate to severe comorbidity assigned using the ACE-27 metric 8 adjusting for age and known PC prognostic factors.
MATERIALS AND METHODS

Patient Population and Treatment
A total of 206 men with adenocarcinoma of the prostate (1992 American Joint Commission on Cancer [AJCC] clinical tumor (T) classification of T1b to T2b) were recruited from 6 Harvard-affiliated hospitals between December 1, 1995, and April 15, 2001 , to participate in the study. After providing informed consent (approved by the institutional review boards at Steward Hospital and Dana-Farber/Harvard Cancer Center), the men were randomized 13 to receive 70 gray of 3-dimensional conformal external-beam RT either alone (104 men) or in combination with 6 months of ADT (102 men). ADT included a luteinizing hormonereleasing hormone agonist and flutamide, a first-generation antiandrogen. Patients were eligible for participation if they had at least 1 of the following unfavorable risk features: prostate-specific antigen (PSA) level >10 ng/mL and 40 ng/mL and a Gleason score of 7 based on biopsy or evidence of extracapsular extension or seminal vesicle invasion on radiographic imaging. All pathologic specimens were reviewed by a dedicated genitourinary pathologist (A.A.R.).
Follow-Up and Determination of Cause of Death
Patients were followed every 3 months for the first 2 years, every 6 months for the next 3 years, and annually thereafter with serologic PSA and testosterone measurement and digital rectal examination; none were lost to follow-up. Patients were followed from randomization until the time of death or last follow-up through the prespecified analysis date of October 9, 2016. Patients signed a waiver of consent for long-term follow-up. Initially, a PSA failure was specified as 2 serial increases in the PSA level of >0.2 ng/mL after a nadir value was achieved.
14 However, a PSA failure later was specified as an increase of 2 ng/mL above the nadir. 15 When patients experienced a PSA failure, they were evaluated using a digital rectal examination, radiographic imaging (either computed tomography or magnetic resonance imaging), and a bone scan to evaluate for distant metastatic disease. If the PSA level reached or exceeded approximately 10 ng/mL, patients were offered salvage ADT. At the time of salvage ADT, the median PSA was 9.6 ng/mL (interquartile range [IQR], 7.55-12.05 ng/mL).
In the current study, death was attributed to either to PC, a CV event, or other causes and the cause of death was assessed by the treating physician and validated based on clinical records. To assign PC as the cause of death, patients were required to have castration-resistant 
Statistical Analysis
Definition of TTR Serum testosterone was measured using the Bayer Assay (Bayer Corporation, Tarrytown, New York), with the lower limit of normal defined as 280 ng/dL. Testosterone recovery was defined as the date when the testosterone level reached the lower limit of normal using the Bayer Assay. TTR was defined as the time interval in months from the end of the 6 months of ADT administration to the date of testosterone recovery.
Comparison of the distribution of clinical factors stratified by comorbidity at randomization Table 1 illustrates the distribution of clinical factors stratified by no or minimal comorbidity versus moderate to severe comorbidity defined using the ACE-27 metric. 8 The distribution of the continuous clinical factors across comorbidity strata including median PSA level, age at randomization, and the TTR were compared using the Wilcoxon rank sum test 16 whereas the distribution of categorical covariates including Gleason score, AJCC 1992 tumor clinical T classification, randomized treatment arm, and salvage ADT use were compared using the chi-square metric. 17 
Regression analyses
Fine and Gray 18 competing risk regression was used to evaluate whether the TTR was associated with the risk of PCSM and CVM among men with no or minimal versus moderate to severe comorbidity adjusting for age and known PC prognostic factors. TTR is a postrandomization covariate and therefore was evaluated as a timedependent covariate. In addition, to assess whether the results differed by comorbidity strata, an interaction term between TTR and comorbidity was included in the model. Time zero was defined as the date of randomization. Unadjusted and adjusted hazard ratios (AHRs) with 95% confidence intervals (95% CIs) and P values were calculated. For the purpose of the model, the categorical covariates of Gleason score and AJCC tumor classification were defined as Gleason score 8 to 10 versus 7 versus 6 (baseline) and T2 versus T1 (baseline), respectively. Finally, Cox regression analysis was used to evaluate whether the TTR was associated with the risk of all-cause mortality (ACM) among men with no or minimal versus those with moderate to severe comorbidity adjusted for age and known prostate cancer prognostic factors. 19 Estimates of PCSM, CVM, or ACM Figures 1, 2, and 3 illustrate estimates of PCSM, CVM, and ACM, respectively, in men with no or minimal versus moderate to severe comorbidity, stratified by no ADT use, TTR 2 years, and TTR >2 years. Cumulative incidence estimates of PCSM and CVM were calculated and Figure 1 . Cumulative incidence estimates of prostate cancerspecific mortality stratified by time to testosterone rebound (TTR) among men with (A) no or minimal comorbidity or (B) moderate to severe comorbidity. Gray 2-sample P values for pairwise comparisons among men with no or minimal comorbidity were as follows: no androgen deprivation therapy (ADT) use versus TTR 2 years: P 5.217; no ADT use versus TTR >2 years: P 5 .0008; and TTR 2 years versus TTR >2 years: P 5.049. Gray 2-sample P values for pairwise comparisons among men with moderate to severe comorbidity were as follows: no ADT use versus TTR 2 years: P 5 .513; no ADT use versus TTR >2 years: P 5 .231; and TTR 2 years versus TTR >2 years: P 5 .245.
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Cancer April 1, 2018 compared using a 2-sided Gray P value. 20 One minus Kaplan-Meier estimates of overall survival or ACM were calculated and compared using a 2-sided log-rank test. 21 To adjust for multiple comparisons, a Bonferroni correction was applied (3 for PCSM and CVM and 4 for ACM; thus, a significant 2-sided P value was considered to be <.0167 and .0125, respectively). Statistical analyses were conducted using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina) for all analyses except for the 2-sided Gray P values, which were conducted using R statistical software (version 3.2.3; R Foundation for Statistical Computing, Auckland, New Zealand). Table 1 illustrates that there were no significant differences in the distribution of clinical and treatment characteristics among men with no or minimal versus moderate to severe comorbidity. However, there was a trend toward more advanced disease among men with moderate to severe compared with no or minimal comorbidity, with Gleason score 8 to 10 PC noted in 24.49% versus 11.46% of men (P 5.06), respectively, and AJCC T2 disease observed in 63.27% versus 48.41% of men (P 5.07), respectively. As shown in the footnote of Table 1 , the median TTR among men with no or minimal comorbidity was 17.5 months for men with a TTR 2 years and 29 months for men with a TTR >2 years. These respective values for men with moderate to severe comorbidity were 20 months and 27 months.
RESULTS
Comparison of the Distribution of Clinical Factors Stratified by Comorbidity at Randomization
Regression Analyses
After a median follow-up of 18.19 (IQR, 16.96-19.14) years, 30 (18.6%), 39 (24.2%), and 92 men (57.1%) died of PC, CV disease, or other causes, respectively, of the 161 deaths observed in the study. As shown in Table 2 , as TTR increased, there was a significant reduction in the risk of PCSM among men with no or minimal comorbidity (AHR, 0.53; 95% CI, 0.34-0.84 [P 5.007]) as well as in men with moderate to severe comorbidity (AHR, 0.37; 95% CI, 0.14-0.99 [P 5.048]). However, for the endpoint of the risk of CVM, increasing TTR was only found to be associated with a significantly increased risk among men with moderate to severe comorbidity (AHR, 1.87, 95% CI, 1.40-2.49 [P <.001]), but not among men with no or minimal comorbidity (AHR, 0.86; 95% CI, 0.57-1.29 [P 5.46]). The interaction term of TTR 3 ACE-27-defined comorbidity was not significant for the endpoint of PCSM (P 5.52) because the risk of PCSM is significantly reduced as TTR increases in men regardless of comorbidity. However, this interaction term was significant for the endpoint of CVM (P 5.001) because the risk of CVM increased only with increasing TTR in men with moderate to severe but not no or minimal comorbidity. Cumulative incidence estimates of cardiovascularspecific mortality stratified by time to testosterone rebound (TTR) among men with (A) no or minimal comorbidity or (B) moderate to severe comorbidity. Gray 2-sample P values for pairwise comparisons among men with no or minimal comorbidity were as follows: no androgen deprivation therapy (ADT) use versus TTR 2 years: P 5 .656; no ADT use versus TTR >2 years: P 5 .222; and TTR 2 years versus TTR >2 years: P 5 .424. Gray 2-sample P values for pairwise comparisons among men with moderate to severe comorbidity were as follows: no ADT use versus TTR 2 years: P 5 .037; no ADT use versus TTR >2 years: P 5 .0002; and TTR 2 years versus TTR >2 years: P 5 .410. As shown in Table 2 Cumulative incidence estimates of PCSM and CVM are shown in Figures 1 and 2 for men with no or minimal versus moderate to severe comorbidity, respectively, stratified by a TTR 2 years, TTR >2 years, or no ADT use. As shown in Figure 1 A, as TTR increased, the cumulative incidence estimates of PCSM decreased (overall P 5.003) in men with no or minimal comorbidity whereas this trend was not statistically significant (overall P 5.32) in men with moderate to severe comorbidity, as shown in Figure 1 B. As shown in Figure 2 A, as TTR increased, the cumulative incidence of CVM was not significantly different in men with no or minimal comorbidity (overall P 5.47), whereas there was a significant increase in these estimates in men with moderate to severe comorbidity, as shown in Figure 2 B (overall P 5.001). One minus Kaplan-Meier estimates of survival or ACM are shown in Figure 3 A and B for men with no or minimal versus moderate to severe comorbidity, respectively, stratified by a TTR 2 years, a TTR >2 years, or no ADT use. As shown in Figure 3 A, estimates of ACM were not significantly different for a TTR 2 years compared with a TTR >2 years (P 5.85). Conversely, there was a near significant reduction in estimates of ACM among men in any TTR subgroup versus no ADT use (P 5.07). Similarly, there was no significant difference in estimates of ACM in men with moderate to severe comorbidity for both TTR subgroups (P 5.20), whereas there was a near significant increase in ACM among men in either TTR subgroup versus the no ADT subgroup (P 5.07). Specifically, the 8-year point estimates for PCSM as shown in Figure 1 A were 0% (95% CI, 0%-0%) and 10.13% (95% CI, 4.70%-17.99%), respectively, in men with no or minimal comorbidity who had a TTR >2 years versus no ADT use and 0% (95% CI, 0%-0%) and 4.0% (95% CI, 0.27%-17.40%), as depicted in Figure 1B in men with moderate to severe comorbidity. These respective estimates for the endpoint of CVM as shown in Figure 2A were 0% (95% CI, 0%-0%) and 7.59% (95% CI, 3.08%-14.83%) in men with no or minimal comorbidity versus 50% (95% CI, 21.47%-73.18%) and 8.0% (95% CI, 1.31%-23.01%) as depicted in Figure 2B in Figure 3 . One minus Kaplan-Meier estimates of overall survival or all-cause mortality stratified by time to testosterone rebound (TTR) among men with (A) no or minimal comorbidity or (B) moderate to severe comorbidity. Two-sample logrank test P values for pairwise comparisons among men with no or minimal comorbidity were as follows: no androgen deprivation therapy (ADT) use versus TTR 2 years: P 5 .21; no ADT use versus TTR >2 years: P 5 .09; TTR 2 years versus TTR >2 years: P 5 .85; and no ADT use versus TTR >0: P 5 .07. Two-sample log-rank test P values for pairwise comparisons among men with moderate to severe comorbidity were as follows: no ADT use versus TTR 2 years: P 5 .01; no ADT use versus TTR >2 years: P 5 .35; TTR 2 years versus TTR >2 years: P 5 .20; and no ADT use versus TTR >0: P 5 .07. men with moderate to severe comorbidity. Finally, these respective estimates for the endpoint of ACM as shown in Figure 3A were 9.30% (95% CI, 3.60%-22.91%) and 25.32% (95% CI, 17.14%-36.44%) in men with no or minimal comorbidity versus 57.14% (95% CI, 33.96%-82.27%) and 44.0% (95% CI, 27.27%-65.21%) as depicted in Figure 3B in men with moderate to severe comorbidity.
DISCUSSION
In the current study, we observed that the risk of PCSM decreased significantly with increasing TTR after the administration of external-beam RT and 6 months of ADT, both in men with no or minimal comorbidity as well as in men with moderate to severe comorbidity, but to a less certain extent in the latter group given the wide 95% CI on the point estimate of the AHR for PCSM. In addition, we noted that the risk of CVM significantly increased as the TTR increased in men with moderate to severe comorbidity but not in men with no or minimal comorbidity. Given that there was no significant difference in ACM estimates in either TTR subgroup, whereas there were near significant differences in ACM estimates among men in either TTR subgroup versus the no ADT subgroup, provides evidence to support using the median TTR in the group with a TTR of 2 years (17.5 months) as the amount of TTR necessary to achieve a reduction in ACM in men with no or minimal comorbidity. Moreover, for men with moderate to severe comorbidity, the median TTR in the group with a TTR of 2 years was 20 months. These results suggest that maintaining a TTR of at least 17.5 months but <20 months may optimize the therapeutic ratio by providing a reduction in ACM in men with no or minimal comorbidity while not increasing ACM in men with moderate to severe comorbidity. Assuming testosterone levels were collected and recorded, RTOG 0815 22 should be able to prospectively assess this hypothesis because men in that randomized controlled trial underwent a prerandomization stratification using the ACE-27 comorbidity metric to no or minimal versus moderate to severe comorbidity and then were randomized to RT with or without 6 months of ADT with a primary endpoint of overall survival. The clinical significance of these findings is that it appears that TTR drives both the reduction in the risk of PCSM and the increased risk of CVM observed in the current study and not simply the duration of ADT administered, and these risks are comorbidity dependent.
This finding provides an opportunity to consider shorter durations of ADT administration in men with moderate to severe comorbidity as opposed to the standard long-term (ie, 28-36 months) administration of ADT despite having high-risk PC. Notably, withholding ADT in men with moderate to severe comorbidity is not recommended given that the risk of PCSM declines with increasing TTR. Instead, reducing the duration of ADT delivered to 18 months 23 or possibly less compared with 28 to 36 months could be considered, in addition to maximizing CV health using medical/surgical management before the initiation of ADT. While the data for 18 months of ADT in men with high-risk PC has not been tested formally using a noninferiority study design against the established standards of 28 to 36 months, one superiority study 23 noted at a median follow-up of 9.4 years that the HR for death was 1.02 (95% CI, 0.81-1.29). This result provides evidence that 36 months is not superior to 18 months of ADT but it is possible that 18 months may be noninferior to 36 months of ADT with respect to overall survival if one is willing to accept with 95% certainty a maximum of a 29% increased risk or 2% on average with 18 months compared to 36 months of ADT use.
Several points require further discussion. First, the observed impact of the TTR on the risk of PCSM may explain why the randomized trials of short-course neoadjuvant ADT before radical prostatectomy (RP) did not demonstrate a reduction in death from PC or prolonged survival, but at most pathologic downstaging, [24] [25] [26] [27] [28] whereas similar studies in men treated with RT observed an improvement in survival due to reduced deaths from PC. 1, 2, 29, 30 Specifically, men enrolled in the neoadjuvant ADT RP trials were on average 5 to 8 years younger (median age range, 62-65 years compared with a median age of 70 years on RT studies) and therefore would be expected to be healthier than men enrolled on the neoadjuvant ADT RT trials because they needed to be surgical candidates. Given the prior work that has established that advancing age is associated with increased TTR, 31 men managed with short-course ADT in RP randomized controlled trials would be expected to have shorter TTRs than similarly managed men enrolled on the neoadjuvant RT randomized controlled trials. As a result, surgically managed men would be less likely to experience a reduced risk of PCSM with short-course ADT because of the relatively short TTR compared with the older men enrolled on the neoadjuvant ADT RT trials given the relationship observed in the current study between increasing TTR and a reduced risk of PCSM. Only the randomized study of surgically treated men found to have pathologically lymph node-positive PC observed a significant prolongation in survival among men randomized to life-long adjuvant as opposed to deferred ADT. 32 In that study, the TTR was extended for the patient's lifetime once ADT was initiated.
Second, based on the current study findings, one could consider an intermittent ADT approach in men with moderate to severe comorbidity and high-risk PC by prescribing 6 months of ADT and subsequently following serum testosterone levels every 3 months for 2 years to ascertain whether testosterone rises above castrate levels to be able to administer additional ADT so that the total length of castration approximates the standard of care of 28 months. Although to the best of our knowledge this approach has not been formally tested in the management of newly diagnosed patients with high-risk PC to assess its impact on survival, it has been tested in the rising PSA setting after RT with or without ADT, in which no significant difference in survival was noted when intermittent versus continuous ADT was used. 33 Therefore, although an intermittent approach as described above has not been shown to decrease CVM, such an approach may be prudent to consider in men with high-risk PC and moderate to severe comorbidity.
Third, a prior decision analysis was conducted to determine the optimal strategy for the use of ADT with respect to PC and CV risk factors and concluded that healthy men expected to survive >7 years from a PC diagnosis would derive the most benefit from the addition of ADT, whereas those with multiple CV risk factors and a shorter remaining life expectancy would be predicted to experience a decrease in survival with ADT. 34 While it has been reported previously that the majority of men categorized to have moderate to severe comorbidity in the current study had CV disease 1 to achieve this comorbidity category, the issue of which specific CV disease or diseases predisposed men to the increased CVM risk with increasing TTR as observed herein remains to be elucidated.
Finally, the associations between TTR and the risk of ACM, while not significant in the multivariable model, had the expected directionality: specifically, a decreased risk of ACM with increasing TTR in men with no or minimal comorbidity (based on a decreased risk of PCSM) and an increased risk of ACM with increasing TTR in men with moderate to severe comorbidity (based on the increased risk of CVM). The explanation for the lack of significance is that the median age of the study cohort was 72.5 years at the time of randomization, and given the median follow-up of 18.19 years, we would expect, as noted in the study, that many men cured of their PC or who did not die of CV disease died of other causes. In fact, the majority of the deaths in the current study (92 of 161 patients or 57.1%) were from other causes. Thus, the ability to observe the impact of one specific cause of death (ie, PCSM or CVM) on the risk of ACM is lessened by the diluting effect of death from non-PC and non-CV causes in both arms of the study.
Despite these considerations, it appears that an increasing TTR following RT and 6 months of ADT reduces the risk of PCSM irrespective of the degree of comorbidity whereas men with moderate to severe comorbidity experience an increased risk of CVM with increasing TTR. Therefore, considering an intermittent course of ADT such that the TTR approaches 18 months, as opposed to the continuous long-term administration of ADT, in men with moderate to severe comorbidity and high-risk PC may reduce the increased risk of CVM we observed without increasing the risk of PCSM.
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